carboplatin + etrumadenant + pembrolizumab + pemetrexed

This is a four-drug combination regimen consisting of carboplatin, etrumadenant, pembrolizumab, and pemetrexed. - **Carboplatin** is a platinum-based alkylating agent that causes DNA crosslinking and apoptosis in rapidly dividing cells[5]. - **Etrumadenant** is an oral small molecule antagonist of adenosine A2A and A2B receptors; it blocks immunosuppressive adenosine signaling in the tumor microenvironment to enhance anti-tumor immune responses[4][6]. - **Pembrolizumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1) on T cells; it acts as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor activity. - **Pemetrexed** is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication by inhibiting multiple enzymes involved in purine and pyrimidine synthesis[10]. This combination has been studied primarily for non-squamous non-small cell lung cancer (NSCLC), particularly in patients with advanced or metastatic disease who may have progressed after prior therapies. The rationale for this regimen is to combine cytotoxic chemotherapy with dual immunomodulation—blocking both the PD-1 pathway and adenosine-mediated suppression—to maximize anti-tumor efficacy[6].

Brand names

KeytrudaNone for combination

Other names

etrumadenant + carboplatin + pembrolizumab + pemetrexed